Novo Nordisk announced that a US District Court judge ruled that one of its patents, which covers the combination use of repaglinide and metformin for the treatment of type 2 diabetes, is invalid and unenforceable.
The Food and Drug Administration is laying out plans to update the 35-year-old system used to approve most medical devices, which has been subject to increasing criticism by public safety advocates.
Ardea Biosciences Inc. said it is publicly offering 2.5 million common shares. The company did not provide financial details on the offering.
Over-the-counter drugmaker Perrigo Co. said it will buy generic drugmaker Paddock Laboratories Inc. for $540 million. Perrigo said Paddock has about $200 million in annual revenue.
Drug developer Mylan Inc. said that the Food and Drug Administration tentatively approved the company's pediatric HIV treatment.
Vertex Pharmaceuticals Inc. said that regulators in the U.S. and Canada will speed their reviews of its drug candidate telaprevir, meaning the hepatitis C therapy could be approved months earlier than usual.
Allos Therapeutics Inc. said its lymphoma drug Folotyn helped some patients who had no response to previous therapies. The results were based on a new analysis of a midstage clinical trial that ended in 2009.
Forest Laboratories Inc. said its depression treatment levomilnacipran failed in a late-stage clinical trial, as the drug was no more effective than a placebo at treating depression.
AMSBIO has announced the launch of ecoHSA - an animal-free preparation of the human albumin gene produced in the seeds of Asian Rice. Commercial human albumin proteins extracted from plasma have multiple and invaluable uses in cell culture work.
Thermo Fisher Scientific Inc. announced its Syncronis HPLC column range. This new range unerringly delivers consistent, predictable separations, from run to run and column to column.
CRI Worldwide, LLC has completed its acquisition of Lifetree Clinical Research, LLC, creating one of the nation's largest research organizations focusing on the conduct and design of early-stage, patient population clinical trials.
CureFAKtor Pharmaceuticals, LLC announced that its lead compound, CFAK-C4 , which is in development for the treatment of pancreatic cancer, has been granted orphan drug designation by the U.S. Food and Drug Administration.
Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation’s discovery in 2008. The hunt is now yielding fruit.
Scientists are reporting an advance in overcoming a major barrier to the use of the genetic material RNA in nanotechnology—the field that involves building machines thousands of times smaller than the width of a human hair and now is dominated by its cousin, DNA.
GlaxoSmithKline and Prosensa announced that the first patient has commenced treatment in the Phase 3 clinical study investigating GSK2402968, in ambulant boys with Duchenne Muscular Dystrophy, who have a dystrophin gene mutation amenable to an exon 51 skip.